Personally, I am enthusiastic about the introduction of this drug. Uh, as I have mentioned, uh, I've worked with bronchiectasis patients for 40 years, and this is the first drug, uh, approved specifically for bronchiectasis. When I talk to patients about it, I, I do mention that. Um, I also discussed, uh, the pathophysiology, uh, including the effect on neutrophil-mediated, uh, inflammation. Uh, I think it's important that they know it's not a steroid, um, and that it is a systemic anti-inflammatory. That, that is, of course, a, a separate discussion about what other diseases might benefit from, uh, drugs with this mechanism. Uh, I also go through the, uh, findings in the two major trials, uh, including, uh, those elements that, uh, the, uh, insurance carriers have picked up on. Uh, specifically, the, the number of, uh, exacerbations per year and the, uh, pulmonary function testing. Um, it's also, uh, interesting that the patients, uh, want to know about side effects, uh, almost before we start the discussion. I usually hold that until after I stress to them, you know, important points that uh there are no contraindications, there are no major drug, drug side effects, and that patients are not immune suppressed or immune compromised. And then I, I go through, uh, you know, a list of the, uh, potential, uh, side effects, uh, of, of the drug, including some that, uh, don't occur, uh, such as GI side effects. Um, but I try to give the, the patients, uh, uh, as much information as I can. It's interesting that almost all of them have already read about the drug. Uh, they usually come armed with, uh, Uh, fear of a specific side effects such as hair loss. Um, but I, I tried to explain that the side effects are, uh, uncommon and, and generally, uh, mild. Um, so far, um, I, that's about all I, uh, that's necessary, uh, to get folks to try the drug. Um, and since there are no, uh, life-threatening, uh, side effects, Uh, and all, almost all of the, uh, side effects that occur are reversible with discontinuation of the drug. Um, it's, it's a really, the, uh, a really clear risk-benefit ratio from my perspective. The potential benefit is very, very big, and the potential risk is very small.
Presenter
